About: Alogliptin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Alogliptin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B49D6-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49D7-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49D9-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49DA-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49DB-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B49D8-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 Mar;30(3):513-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18405789 # Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 Mar;30(3):499-512. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18405788 # FDA label # Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22686547 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Terminal half-life = 21 hours (en)
http://linked.open...ugbank/indication	Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (en)
sameAs	Alogliptin
Title	Alogliptin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/chebi/72323 http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/drugbank/DB06203 http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/kegg-drug/D06553 http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/national-drug-code-directory/64764-250-30 http://linked.opendata.cz/resource/drugbank/drug/DB06203/identifier/wikipedia/Alogliptin
http://linked.open...mechanismOfAction	Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 ( GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. GIP and GLP-1 stimulate glucose dependent secretion of insulin in pancreatic beta cells. GLP-1 has the additional effects of suppressing glucose dependent glucagon secretion, inducing satiety, reducing food intake, and reducing gastric emptying. (en)
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/6303640 http://linked.opendata.cz/resource/drugbank/patent/6303661 http://linked.opendata.cz/resource/drugbank/patent/6150383 http://linked.opendata.cz/resource/drugbank/patent/6211205 http://linked.opendata.cz/resource/drugbank/patent/6329404 http://linked.opendata.cz/resource/drugbank/patent/6890898 http://linked.opendata.cz/resource/drugbank/patent/7078381 http://linked.opendata.cz/resource/drugbank/patent/7459428 http://linked.opendata.cz/resource/drugbank/patent/7807689 http://linked.opendata.cz/resource/drugbank/patent/8173663 http://linked.opendata.cz/resource/drugbank/patent/8288539
http://linked.open...outeOfElimination	Renal excretion (76%) and feces (13%). 60% to 71% of the dose is excreted as unchanged drug in the urine. (en)
http://linked.open.../drugbank/synonym	Alogliptina (en) Alogliptine (en) Alogliptinum (en) SYR-322 (en)
http://linked.open...drugbank/toxicity	Common adverse reactions (reported in ≥4% of patients treated with alogliptin 25 mg and more frequently than in patients who received placebo) are: nasopharyngitis, headache, and upper respiratory tract infection. (en)
http://linked.open...umeOfDistribution	Following a single, 12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues. (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/68-20-05
http://linked.open.../drugbank/mixture	Kazano Oseni
http://linked.open...nk/proteinBinding	Alogliptin is 20% bound to plasma proteins. (en)
http://linked.open...ogy/drugbank/salt	(en)
http://linked.open...ynthesisReference	Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura, "SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE." U.S. Patent US20100092551, issued April 15, 2010. (en)
foaf:page	http://www.drugs.com/mtm/alogliptin.html http://www.rxlist.com/nesina-drug/patient-images-side-effects.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B49E0-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B49E6-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B49E5-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B49E2-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B49E3-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B49E4-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B49DE-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B49F5-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B49DC-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B49DF-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B49DD-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Alogliptin
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B49EC-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B49ED-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B49E7-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B49E8-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B49EA-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B49E9-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B49EB-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	The pharmacokinetics of NESINA was also shown to be similar in healthy subjects and in patients with type 2 diabetes. When single, oral doses up to 800 mg in healthy subjects and type 2 diabetes patients are given, the peak plasma alogliptin concentration (median Tmax) occurred 1 to 2 hours after dosing. Accumulation of aloglipin is minimal. The absolute bioavailability of NESINA is approximately 100%. Food does not affect the absorption of alogliptin. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	850649-61-5 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	Renal clearance = 9.6 L/h (this value indicates some active renal tubular secretion); Systemic clearance = 14.0 L/h. (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B49F1-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B49F3-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B49F4-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B49F0-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B49EF-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B49F2-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B49E1-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B49EE-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 117 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software